Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kotobuki Pharmaceutical Co., Ltd.

http://www.kotobuki-pharm.co.jp/eng/index.html

Latest From Kotobuki Pharmaceutical Co., Ltd.

Deal Watch: Lilly Finds New Partners For Genetic Disorders, Protein Degradation

Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.

Deals Business Strategies

Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer

Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.

Financing Business Strategies

Astellas Stays Ahead of Daiichi Sankyo In AML With CHMP Nod For Xospata

A positive opinion for its FLT3 inhibitor for acute myeloid leukemia gives Astellas a further advantage over its Japanese competitor's same-class offering, quizartinib.

Drug Review Cancer

Purple Patch For Pharma/Biotech R&D As NAS Launches Reach Record High

The pharma and biotech industries enjoyed their most productive year since the turn of the century in terms of number of novel products launched worldwide in 2018.

Launches Analysis
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register